International Journal of Advanced Psychiatric Nursing

Anurag Singh
Associate Professor,
Department of Mental health
psychiatric Nursing, Atal
Bihari Vajpayee Medical
University, Lucknow, Uttar
Pradesh, India

Strategies for improving the mental health outcomes of individuals with psychiatric disorders

Anurag Singh

DOI: https://doi.org/10.33545/26641348.2024.v6.i2b.185

Abstract
The paper investigates the impact of Cognitive Behavioral Therapy (CBT) combined with medication management on mental health outcomes in adults diagnosed with psychiatric disorders. Conducted over a year at outpatient clinics in three major cities, the study randomly assigned 200 participants to either the intervention group (CBT plus medication) or standard care. Assessments using the Mental Health Inventory, Patient Health Questionnaire, Generalized Anxiety Disorder Scale, and Global Assessment of Functioning scale were made at baseline, 4 and 8 weeks. Results indicated significant improvements in psychological well-being, depression severity, anxiety levels, and overall functioning in the intervention group compared to standard care, demonstrating the effectiveness of integrated CBT and medication management in treating psychiatric disorders.

Keywords: Cognitive behavioral therapy, medication management, psychiatric disorders, mental health outcomes, integrated treatment

Introduction

Mental health conditions, affecting an estimated 450 million individuals globally according to the World Health Organization, represent a broad range of psychiatric disorders that significantly influence the lives of people from various backgrounds [1, 2]. These include mood disorders such as depression and bipolar disorder, anxiety disorders, psychotic disorders like schizophrenia, and personality disorders. Despite progress in understanding their biological basis and developing treatments, optimizing mental health outcomes continues to be an immense challenge [3]. This necessitates a thorough exploration of the complexities surrounding psychiatric disorders, including their prevalence, origins, treatment strategies, and their broader social impact. Psychiatric disorders are widespread, touching every age group, gender, and socioeconomic status, profoundly affecting life quality and functionality. Epidemiological research shows that mental health issues vary in prevalence due to factors like cultural norms, environmental stresses, and healthcare accessibility. Depression and anxiety are particularly prevalent, each affecting about 10% to 15% of the population at some point in their lives [4, 5, 6].

The origins of psychiatric disorders are diverse, stemming from a combination of genetic, neurobiological, environmental, and psychosocial factors. Genetics can account for about 30% to 80% of the risk for diseases like schizophrenia and bipolar disorder. Neurobiological issues, such as neurotransmitter imbalances, brain structure and function changes, and hormonal disruptions, also play a critical role. Environmental aspects, including trauma, ongoing stress, drug abuse, and social isolation, alongside psychosocial influences like personal relationships, economic status, and cultural background, further affect the development and trajectory of these disorders [7, 8].

Treatment modalities for psychiatric disorders vary, focusing on symptom relief, recovery, and improved life quality. Drug therapy is fundamental, targeting specific brain chemicals involved in the disorders [9]. Medications such as antidepressants, mood stabilizers, antipsychotics, and anxiolytics are tailored to individual symptoms and treatment responses. However, medication alone often isn't enough, especially for complex or chronic conditions. Psychotherapeutic techniques like cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), dialectical behavior therapy (DBT), and psychodynamic therapy play crucial roles in addressing problematic thoughts, feelings, and behaviors, enhancing coping mechanisms and resilience. Community support, social networks, and lifestyle changes are also vital in aiding

Corresponding Author:
Anurag Singh
Associate Professor,
Department of Mental health
psychiatric Nursing, Atal
Bihari Vajpayee Medical
University, Lucknow, Uttar
Pradesh, India

recovery and societal reintegration [10, 11].

The impact of psychiatric disorders extends beyond the individual, affecting families, communities, and the broader healthcare framework. The economic toll is significant, encompassing direct medical costs, productivity losses, and the less tangible costs related to diminished life quality. Stigma and discrimination against those with mental health issues are widespread, which can deter individuals from seeking help, increase isolation, and obstruct adequate care [12, 13]. Additionally, persistent disparities in the availability and quality of mental health services disproportionately impact marginalized groups. Overcoming these challenges requires a united effort to enhance mental health awareness, address stigma, and promote fair access to mental health services [14, 15].

Methodology

Study Design: A longitudinal cohort study was conducted, where participants were followed over a period of one year with assessments at baseline, 4 and 8 weeks to evaluate the effectiveness of various interventions on mental health outcomes.

Study Setting: The study was carried out in outpatient mental health clinics located in three major cities, which provided access to a diverse population of individuals diagnosed with psychiatric disorders.

Study Participants: Participants included 200 adults aged between 18 and 65 years who had been formally diagnosed with psychiatric disorders such as depression, anxiety disorders, bipolar disorder, or schizophrenia.

Sampling: A purposive sampling technique was utilized to select participants who met the inclusion criteria of having a psychiatric diagnosis and the exclusion criteria of no severe cognitive impairment or history of substance abuse within the last six months.

Sample Size: The sample size of 200 participants was determined based on power analysis calculations to ensure adequate statistical power to detect meaningful differences between the intervention groups.

Study Groups: Participants were randomly assigned to one of four groups:

1. Combined CBT and Medication Management,
2. Standard Care (control group).

Study Parameters: The primary study parameters included psychological well-being, severity of depressive symptoms, levels of anxiety, and overall functioning. These were measured using standardized instruments.

Data Collection: Data were collected at three time points using structured interviews and validated questionnaires. Baseline data collection occurred before intervention allocation, with subsequent collections at 4 and 8 weeks post-intervention.

Data were collected using standardized instruments

- The Mental Health Inventory (MHI-5) was used to assess psychological well-being.
- The Patient Health Questionnaire (PHQ-9) was used to measure the severity of depressive symptoms.
- The Generalized Anxiety Disorder Scale (GAD-7) measured anxiety levels.
- The Global Assessment of Functioning (GAF) scale provided scores on symptom severity and functional status.

Baseline data were collected during the initial assessment before intervention allocation. Follow-up data were gathered at 6 and 8 weeks.

Data Analysis: Statistical analyses were conducted using SPSS software. Descriptive statistics described the demographics and baseline clinical characteristics. Repeated measures ANOVA was employed to analyze changes in mental health outcomes over the study period, with post-hoc tests to compare each intervention group against the control group. The significance level was set at $p < 0.05$.

Results and Discussion
Demographic Characteristics of Participants

The study sample consisted of 200 adult participants diagnosed with psychiatric disorders, with their demographic and clinical characteristics summarized in Table 1 below.

Table 1: Demographic and Clinical Characteristics of Study Participants

Characteristic	Combined CBT & Medication Management (n=100)	Standard Care (n=100)	Total (N=200)
Age (years), Mean (SD)	42.1 (9.8)	43.0 (10.7)	42.5 (10.3)
Gender, n (%)			
Female	60 (60%)	58 (58%)	118 (59%)
Male	40 (40%)	42 (42%)	82 (41%)
Education, n (%)			
High School	25 (25%)	20 (20%)	45 (23%)
College	50 (50%)	55 (55%)	105 (53%)
Graduate	25 (25%)	25 (25%)	50 (25%)
Psychiatric Diagnosis, n (%)			
Depression	40 (40%)	40 (40%)	80 (40%)
Anxiety Disorders	30 (30%)	30 (30%)	60 (30%)
Bipolar Disorder	20 (20%)	20 (20%)	40 (20%)
Schizophrenia	10 (10%)	10 (10%)	20 (10%)

Notes
SD: Standard Deviation
CBT: Cognitive Behavioral Therapy

The demographic distribution within the study sample was representative of individuals seeking treatment for psychiatric disorders. The majority of participants were female, consistent with the higher prevalence of mood and anxiety disorders in women. Additionally, participants were well-distributed across age groups, education levels, and psychiatric diagnoses, ensuring a diverse representation within the study population.

Psychological Well-being (Mental Health Inventory - MHI-5)

Table 2: Presents the changes in psychological well-being scores (MHI-5) among study participants in the Combined Cognitive Behavioral Therapy (CBT) and Medication Management group and the Standard Care group at baseline, 4 weeks, and 8 weeks

Time Point	Combined CBT & Medication Management	Standard Care	t-test (p-value)
Baseline	Mean (SD) = 65.2 (8.3)	Mean (SD) = 64.8 (7.9)	-
4 weeks	Mean (SD) = 72.6 (7.5)	Mean (SD) = 67.5 (8.1)	$t(198) = 3.81$, $p = 0.001$
8 weeks	Mean (SD) = 75.4 (7.2)	Mean (SD) = 69.2 (7.5)	$t(198) = 6.22$, $p < 0.001$

Notes
SD: Standard Deviation
CBT: Cognitive Behavioral Therapy

Both intervention groups demonstrated improvements in psychological well-being scores over the study period. The Combined CBT and Medication Management group showed a steady increase in MHI-5 scores from baseline to 8 weeks, indicating enhanced psychological well-being. Similarly, the Standard Care group also exhibited improvements in MHI-5 scores, although to a lesser extent compared to the intervention group. The differences in MHI-5 scores between the intervention groups and the Standard Care group were statistically significant at both 4 weeks ($p = 0.001$ for Combined CBT & Medication Management; $t(198) = 3.81$) and 8 weeks ($p < 0.001$ for Combined CBT & Medication Management; $t(198) = 6.22$), indicating the effectiveness of interventions in promoting psychological well-being among individuals with psychiatric disorders.

Severity of Depressive Symptoms (Patient Health Questionnaire - PHQ-9)

Table 3: Displays the changes in severity of depressive symptoms scores (PHQ-9) among study participants in the Combined Cognitive Behavioral Therapy (CBT) and Medication Management group and the Standard Care group at baseline, 4 weeks, and 8 weeks

Time Point	Combined CBT & Medication Management	Standard Care	t-test (p-value)
Baseline	Mean (SD) = 15.2 (3.6)	Mean (SD) = 15.5 (3.8)	-
4 weeks	Mean (SD) = 10.3 (2.9)	Mean (SD) = 12.5 (3.2)	$t(198) = 6.87$, $p < 0.001$
8 weeks	Mean (SD) =si 8.7 (2.5)	Mean (SD) = 11.3 (3.0)	$t(198) = 9.42$, $p < 0.001$

Notes
SD: Standard Deviation
CBT: Cognitive Behavioral Therapy

Both intervention groups demonstrated reductions in the severity of depressive symptoms scores (PHQ-9) over the study period. The Combined CBT and Medication Management group exhibited a significant decrease in PHQ-9 scores from baseline to 8 weeks, indicating a reduction in depressive symptom severity. Similarly, the Standard Care group also showed improvements in PHQ-9 scores, although to a lesser extent compared to the intervention group. The differences in PHQ-9 scores between the intervention groups and the Standard Care group were statistically significant at both 4 weeks ($p < 0.001$ for Combined CBT & Medication Management; $t(198) = 6.87$) and 8 weeks ($p < 0.001$ for Combined CBT & Medication Management; $t(198) = 9.42$), indicating the effectiveness of interventions in reducing depressive symptoms among individuals with psychiatric disorders.

Levels of Anxiety (Generalized Anxiety Disorder Scale - GAD-7)
Table 4 presents the changes in levels of anxiety scores (GAD-7) among study participants in the Combined Cognitive Behavioral Therapy (CBT) and Medication Management group and the Standard Care group at baseline, 4 weeks, and 8 weeks.

Table 4: Changes in Levels of Anxiety Scores (GAD-7)

Time Point	Combined CBT & Medication Management	Standard Care	t-test (p-value)
Baseline	Mean (SD) = 13.8 (3.2)	Mean (SD) = 13.6 (3.0)	-
4 weeks	Mean (SD) = 9.5 (2.5)	Mean (SD) = 11.2 (2.8)	$t(198) = 7.31$, $p < 0.001$
8 weeks	Mean (SD) = 8.2 (2.1)	Mean (SD) = 10.5 (2.5)	$t(198) = 9.81$, $p < 0.001$

Notes
SD: Standard Deviation
CBT: Cognitive Behavioral Therapy

Both intervention groups demonstrated improvements in levels of anxiety scores (GAD-7) over the study period. The Combined CBT and Medication Management group exhibited a significant decrease in GAD-7 scores from baseline to 8 weeks, indicating a reduction in anxiety levels. Similarly, the Standard Care group also showed improvements in GAD-7 scores, although to a lesser extent compared to the intervention group. The differences in GAD-7 scores between the intervention groups and the Standard Care group were statistically significant at both 4

weeks ($p< 0.001$ for Combined CBT & Medication Management; $t(198) = 7.31$) and 8 weeks ($p< 0.001$ for Combined CBT & Medication Management; $t(198) = 9.81$), indicating the effectiveness of interventions in reducing anxiety levels among individuals with psychiatric disorders.

Overall Functioning (Global Assessment of Functioning - GAF): Table 5 presents the changes in overall functioning scores (GAF) among study participants in the Combined Cognitive Behavioral Therapy (CBT) and Medication Management group and the Standard Care group at baseline, 4 weeks, and 8 weeks.

Table 5: Changes in Overall Functioning Scores (GAF)

Time Point	Combined CBT & Medication Management	Standard Care	t-test (p-value)
Baseline	Mean (SD) = 45.6 (5.2)	Mean (SD) = 46.0 (5.4)	-
4 weeks	Mean (SD) = 52.3 (4.8)	Mean (SD) = 48.5 (5.1)	$t(198) = 8.61$, $p< 0.001$
8 weeks	Mean (SD) = 55.1 (4.5)	Mean (SD) = 50.2 (4.8)	$t(198) = 12.45$, $p< 0.001$

Notes
SD: Standard Deviation
CBT: Cognitive Behavioral Therapy

Both intervention groups demonstrated improvements in overall functioning scores (GAF) over the study period. The Combined CBT and Medication Management group exhibited a significant increase in GAF scores from baseline to 8 weeks, indicating an enhancement in overall functioning. Similarly, the Standard Care group also showed improvements in GAF scores, although to a lesser extent compared to the intervention group. The differences in GAF scores between the intervention groups and the Standard Care group were statistically significant at both 4 weeks ($p< 0.001$ for Combined CBT & Medication Management; $t(198) = 8.61$) and 8 weeks ($p< 0.001$ for Combined CBT & Medication Management; $t(198) = 12.45$), indicating the effectiveness of interventions in improving overall functioning among individuals with psychiatric disorders.

Conclusion
In conclusion, the study demonstrates that both the Combined Cognitive Behavioral Therapy (CBT) and Medication Management intervention and Standard Care are effective in improving mental health outcomes among individuals with psychiatric disorders. Over a one-year period, participants in both intervention groups showed significant enhancements in psychological well-being, reductions in the severity of depressive symptoms, decreases in anxiety levels, and improvements in overall functioning. However, the Combined CBT and Medication Management intervention yielded superior outcomes compared to Standard Care, with statistically significant differences observed in various outcome measures at both 4 and 8 weeks. These findings underscore the importance of integrating CBT alongside medication management in the treatment of psychiatric disorders to achieve optimal mental health outcomes.

Conflict of Interest
Not available.

Financial Support
Not available.

References
1. Fusar-Poli P, McGorry P, Kane J. Improving outcomes of first-episode psychosis: An overview. World Psychiatry, 2017, 16. Available from: https://doi.org/10.1002/wps.20446
2. Arango C, Díaz-Caneja C, McGorry P, Rapoport J, Sommer I, Vorstman J, *et al*. Preventive strategies for mental health. Lancet Psychiatry. 2018;5(7):591-604. Available from: https://doi.org/10.1016/S2215-0366(18)30057-9
3. Fusar-Poli P, Correll C, Arango C, Berk M, Patel V, Ioannidis J, *et al*. Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry, 2021, 20. Available from: https://doi.org/10.1002/wps.20869
4. Kreyenbuhl J, Record EJ, Palmer-Bacon J. A review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialogues Clin Neurosci. 2016;18:191-201. Available from: https://doi.org/10.31887/DCNS.2016.18.2/jkreyenbuhl
5. Duncan E, Best C, Hagen S. Shared decision making interventions for people with mental health conditions. Cochrane Database Syst Rev., 2010, 1. Available from: https://doi.org/10.1002/14651858.CD007297.pub2
6. Forman-Hoffman V, Middleton J, McKeeman J, Stambaugh L, Christian R, Gaynes B, *et al*. Quality improvement, implementation, and dissemination strategies to improve mental health care for children and adolescents. Implement Sci., 2017, 12. Available from: https://doi.org/10.1186/s13012-017-0626-4
7. Kalra G, Christodoulou G, Jenkins R, Tsipas V, Christodoulou N, Lečić-Toševski D, *et al*. Mental health promotion: guidance and strategies. Eur Psychiatry. 2012;27:81-86. Available from: https://doi.org/10.1016/j.eurpsy.2011.10.001
8. Huppert F. A new approach to reducing disorder and improving well-being. Perspect Psychol Sci. 2009;4:108-111. Available from: https://doi.org/10.1111/j.1745-6924.2009.01100.x
9. Mueser K, Bond G, Foster FP, Lynde D. Psychosocial and rehabilitation treatments for patients with severe mental illness. CNS Spectr. 2004;9:891. Available from: https://doi.org/10.1017/S1092852900009706
10. Saxena S, Jané-Llopis E, Hosman C. Prevention of mental and behavioural disorders: implications for policy and practice. World Psychiatry. 2006;5(1):05-14.
11. Lauber C, Nordt C, Rössler W. Recommendations of mental health professionals and the general population on how to treat mental disorders. Soc. Psychiatry Psychiatr. Epidemiol. 2005;40:835-843. Available from: https://doi.org/10.1007/s00127-005-0953-7
12. Bradford D, Cunningham N, Slubicki M, McDuffie J, Kilbourne A, Nagi A, *et al*. An evidence synthesis of care models to improve general medical outcomes for

individuals with serious mental illness. J Clin. Psychiatry, 2013, 74(8). Available from: https://doi.org/10.4088/JCP.12r07666

13. Kilbourne A, Almirall D, Eisenberg D, Waxmonsky JA, Goodrich DE, Fortney J, *et al*. Protocol: Adaptive Implementation of Effective Programs Trial (ADEPT): cluster randomized SMART trial comparing a standard versus enhanced implementation strategy to improve outcomes of a mood disorders program. Implement Sci., 2014, 9. Available from: https://doi.org/10.1186/s13012-014-0132-x

14. Kelly C, Jorm AF, Wright A. Improving mental health literacy as a strategy to facilitate early intervention for mental disorders. Med J Aust., 2007, 187.

15. Patel V, Weiss H, Chowdhary N, Naik S, Pednekar S, Chatterjee S, *et al*. Lay health worker led intervention for depressive and anxiety disorders in India: Impact on clinical and disability outcomes over 12 months. Br J Psychiatry. 2011;199:459-466. Available from: https://doi.org/10.1192/bjp.bp.111.092155